See more : MS Young Adventure Enterprise, Inc. (MSYN) Income Statement Analysis – Financial Results
Complete financial analysis of Altamira Therapeutics Ltd. (CYTO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Altamira Therapeutics Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Shin-Etsu Chemical Co., Ltd. (4063.T) Income Statement Analysis – Financial Results
- Buxton Resources Limited (BUX.AX) Income Statement Analysis – Financial Results
- NorthIsle Copper and Gold Inc. (NCX.V) Income Statement Analysis – Financial Results
- Green Mountain Development Corp. (GMND) Income Statement Analysis – Financial Results
- Watts International Maritime Company Limited (2258.HK) Income Statement Analysis – Financial Results
Altamira Therapeutics Ltd. (CYTO)
About Altamira Therapeutics Ltd.
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 305.62K | 63.88K | 174.48K | -56.00K | 1.27M | 322.00K | -414.00K | -67.00K | 3.01M | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 1.44M | 2.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -1.14M | -2.18M | 174.48K | -56.00K | 1.27M | 322.00K | -414.00K | -67.00K | 3.01M | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | -372.44% | -3,407.33% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 3.04M | 19.68M | 8.94M | 2.86M | 3.33M | 6.69M | 19.21M | 24.78M | 26.54M | 17.70M | 13.25M | 3.99M |
| General & Administrative | 3.09M | 3.52M | 4.90M | 2.59M | 3.93M | 4.26M | 5.15M | 5.41M | 4.34M | 4.49M | 1.31M | 589.53K |
| Selling & Marketing | 15.35K | 2.38M | 1.50M | 95.66K | 113.96K | 43.82K | 199.48K | 45.65K | 72.56K | 237.72K | 479.03K | 86.23K |
| SG&A | 3.12M | 5.90M | 6.39M | 2.59M | 3.93M | 4.26M | 5.15M | 5.41M | 4.34M | 4.49M | 1.31M | 589.53K |
| Other Expenses | 0.00 | -586.73K | -409.93K | 0.00 | 0.00 | 215.72K | 87.59K | 34.06K | 62.20K | 73.43K | 49.42K | 34.28K |
| Operating Expenses | 6.54M | 24.99M | 14.92M | 5.46M | 7.26M | 10.95M | 24.36M | 30.22M | 30.88M | 22.19M | 14.62M | 4.61M |
| Cost & Expenses | 6.54M | 26.44M | 17.16M | 5.46M | 7.26M | 10.95M | 24.36M | 30.22M | 30.88M | 22.19M | 14.62M | 4.61M |
| Interest Income | 730.20K | 969.00 | 3.22K | 258.00 | 17.88K | 0.00 | 53.57K | 67.57K | 37.00K | 52.13K | 74.04K | 5.83K |
| Interest Expense | 0.00 | 911.87K | 189.70K | 135.15K | 28.63K | 1.07M | 1.64M | 828.55K | 8.00K | 49.64K | 50.18K | 0.00 |
| Depreciation & Amortization | 5.92M | 118.89K | 76.36K | 20.04K | 30.82K | 72.71K | 122.78K | 97.60K | 92.78K | 73.98K | 37.52K | 9.24K |
| EBITDA | -1.35M | -17.64M | -6.72M | -5.26M | -7.24M | -10.95M | -24.31M | -30.06M | -30.84M | -22.19M | -14.51M | -4.60M |
| EBITDA Ratio | 0.00% | -8,511.54% | -26,643.21% | -3,027.89% | 12,930.83% | -865.25% | -7,548.97% | 7,260.41% | 46,031.34% | -737.55% | 0.00% | 0.00% |
| Operating Income | -5.92M | -26.13M | -17.10M | -5.28M | -7.26M | -10.95M | -24.36M | -30.22M | -30.88M | -22.19M | -14.62M | -4.61M |
| Operating Income Ratio | 0.00% | -8,550.76% | -26,767.78% | -3,028.04% | 12,962.76% | -865.25% | -7,565.61% | 7,300.31% | 46,086.57% | -737.59% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.35M | -645.64K | -1.46M | -2.94M | 433.41K | -380.10K | -66.00K | -570.03K | 1.17M | 4.01M | -82.89K | 8.09K |
| Income Before Tax | -7.27M | -26.54M | -17.37M | -8.22M | -6.83M | -11.33M | -24.43M | -30.79M | -29.71M | -18.19M | -14.70M | -4.60M |
| Income Before Tax Ratio | 0.00% | -8,683.69% | -27,188.48% | -4,712.11% | 12,188.82% | -895.28% | -7,586.10% | 7,438.00% | 44,335.82% | -604.35% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -10.33K | 21.62K | -21.28K | -193.84K | 162.18K | -17.77K | -131.06K | -84.78K | -892.18K | 305.75K | 0.00 |
| Net Income | -7.27M | -26.53M | -17.39M | -8.20M | -6.63M | -11.50M | -24.41M | -30.66M | -29.71M | -18.19M | -15.00M | -4.60M |
| Net Income Ratio | 0.00% | -8,680.31% | -27,222.33% | -4,699.91% | 11,842.68% | -908.09% | -7,580.58% | 7,406.34% | 44,335.82% | -604.35% | 0.00% | 0.00% |
| EPS | -14.81 | -582.58 | -525.13 | -545.41 | -455.96 | -2.89K | -22.32K | -35.73K | -36.79K | -26.27K | -33.25K | -10.20K |
| EPS Diluted | -14.80 | -582.58 | -525.13 | -545.41 | -455.96 | -2.89K | -22.32K | -35.73K | -36.79K | -26.27K | -33.25K | -10.20K |
| Weighted Avg Shares Out | 491.00K | 45.54K | 33.12K | 15.04K | 14.55K | 3.98K | 1.09K | 858.20 | 807.40 | 692.30 | 451.30 | 451.30 |
| Weighted Avg Shares Out (Dil) | 491.26K | 45.54K | 33.12K | 15.04K | 14.55K | 3.98K | 1.09K | 858.20 | 807.40 | 692.30 | 451.30 | 451.30 |
Here's Why Auris (CYTO) Is a Great 'Buy the Bottom' Stock Now
Auris (CYTO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Altamira Therapeutics Provides Update on Nasdaq Listing
Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that...
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that its associate company Altamira Medica Ltd. obtained extended ISO 13485 certification for its quality management system, including henceforth also production activities....
Altamira Therapeutics Ltd. (CYTO) Q2 2024 Earnings Call Transcript
Altamira Therapeutics Ltd. (NASDAQ:CYTO ) Q2 2024 Results Conference Call September 24, 2024 8:30 AM ET Company Participants Thomas Meyer - Founder, Chairman & Chief Executive Officer Covadonga Paneda - Chief Operating Officer Conference Call Participants Hunter Diamond - Diamond...
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
Hamilton, Bermuda, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today provided a business update and reported its first...
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
Hamilton, Bermuda, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it will host its First Half 2024 Financial...
Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering
Hamilton, Bermuda, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced the closing of its previously announced public...
Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering
Hamilton, Bermuda, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq: CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced the pricing of a public offering...
Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11
Hamilton, Bermuda, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that its founder, Chairman, and CEO...
REPEAT -- Diamond Equity Research Releases Update Note on Altamira Therapeutics Ltd. (NASDAQ: CYTO)
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on Altamira Therapeutics Ltd. (NASDAQ: CYTO). The update note includes detailed...
Source: https://incomestatements.info
Category: Stock Reports